Take Home Messages
• Evaluation of tumor growth rate is essential to predict
what we could expect with each therapy
• RECIST do not take into account tumor dynamics:
validation of TGR in NETs is ongoing
• The CLARINET study has resolved several questions
regarding the efficacy of Lanreotide in NETs:
• Primary site / Grade / Hepatic tumor load
• “Stable” and progressive disease
• The antitumoral effect of Lanreotide is currently being
tested in several situations
